References
- Chekanov MO, Synyugin AR, Lukashov SS, Yarmoluk SM. The synthesis of 2-phenylisothiazolidine-3-one dioxide derivatives as inhibitors of protein kinase CK2. Ukr Bioorg Acta 2009;7:62–4
- Shoichet BK, Stroud RM, Santi DV, et al. Structure-based discovery of inhibitors of thymidylate synthase. Science 1993;259:1445–50
- Bodian DL, Yamasaki RB, Buswell RL, et al. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993;32:2967–78
- Ring CS, Sun E, McKerrow JH, et al. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA 1993;90:3583–7
- Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001;15:411–28
- Yakovenko OY, Oliferenko AA, Golub AG, et al. The new method of distribution integrals evaluations for high throughput virtual screening. Ukrainica Bioorganica Acta 2007;1:52–62
- Yakovenko OY, Li YY, Oliferenko AA, et al. Ab initio parameterization of YFF1, a universal force field for drug-design applications. J Mol Model 2012;18:663–73
- Yakovenko OY, Oliferenko AA, Bdzhola VG, et al. Kirchhoff atomic charges fitted to multipole moments: implementation for a virtual screening system. J Comput Chem 2008;29:1332–43
- Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Mod 2001;7:306–17
- Prykhod'ko AO, Yakovenko OY, Golub AG, et al. Evaluation of 4H-4-chromenone derivatives as inhibitors of protein kinase CK2. Biopolym Cell 2005;21:1–6
- Meggio F, Pagano M, Moro S, et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004;43:12931–6
- Synyugin АR, Chekanov MO, Lukashov SS, Yarmoluk SM. Synthesis of (1,1-dioxido-3-oxoisothiazolidin-2-yl)benzenamides. Ukr Bioorg Acta 2008;6:28–32
- Backes AC, Zech B, Felber B, et al. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin Drug Discov 2008;3:1409–25
- Sarno S, Salvi M, Battistutta R, et al. Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 2005;1754:263–70
- Greenstein JP, Winitz M. Chemistry of the amino acids. New York – London – Sydney – Toronto: John Wiley and Sons; 1961
- Prudent R, Moucadel V, Nguyen CH, et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010;70:9865–74
- Morshed MN, Muddassar M, Pasha FA, Cho SJ. Pharmacophore identification and validation study of CK2 inhibitors using CoMFA/CoMSIA. Chem Biol Drug Des 2009;74:148–58